SERENACE

This brand name is authorized in Australia, Japan, New Zealand, South Africa.

Active ingredients

The drug SERENACE contains one active pharmaceutical ingredient (API):

1	Haloperidol UNII J6292F8L3D - HALOPERIDOL
	Haloperidol is an antipsychotic belonging to the butyrophenones group. It is a potent central dopamine type 2 receptor antagonist, and at recommended doses, has low alpha-1 antiadrenergic activity and no antihistaminergic or anticholinergic activity.
	Read more about Haloperidol

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
SERENACE Tablet	MPI, EU: SmPC	Health Products Regulatory Authority (IE)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N05AD01	Haloperidol	N Nervous system → N05 Psycholeptics → N05A Antipsychotics → N05AD Butyrophenone derivatives
Discover more medicines within N05AD01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	12519X, 2761H, 2763K, 2767P, 2768Q, 2770T, 3456X
JP	医薬品医療機器総合機構	1179020C1191, 1179020F1210, 1179020F2038, 1179020F3255, 1179020F5037, 1179404A1070
NZ	Medicines and Medical Devices Safety Authority	1216, 1217, 1218, 1219, 1220
ZA	Health Products Regulatory Authority	G/2.6.5/96, K/2.6.5/72